氨力农对慢性肺原性心脏病肺动脉压力的临床观察  

The Observation of Pulmonary Artery Pressure on Chronic Pulmonary Heart Disease Treated with Amrinone

作　　者：段玉香[1] 赵美华[1] 高中度[1] 

机构地区：[1]上海市长宁区同仁医院,上海200050

出　　处：《河北医学》2009年第4期386-388,共3页Hebei Medicine

摘　　要：目的:观察氨力农对慢性肺心病患者的临床疗效及对肺动脉平均压(PAPm)的影响。方法:将50例诊断为慢性肺原性心脏病的患者随机分为2组,治疗组25例,在心衰的常规治疗基础上加用氨力农150 mg/d,共7 d;对照组25例,在心衰常规治疗基础上加用立其丁20 mg/d,共7 d,观察治疗前后两周各组及组间心功能分级、超声心动图测肺动脉平均压力的变化并进行疗效比较。结果:两组治疗后较治疗前相比心功能均有不同程度的改善,但治疗组更为明显,差异有显著性;同时治疗组肺动脉平均压显著降低。结论:氨力农对慢性肺心病心力衰竭患者有明显疗效,同时能显著降低肺动脉平均压,使用安全。Objective： To observe the effect of amrinone in patients with chronic pulmonary heart disease and the clinical efficacy of pulmonary artery pressure （PAPm）. Method： 50 patiens with chronic pulmonary heart disease were randomly divided into 2 groups, treatment group 25 cases（ n = 25, amrinone 150 mg / day, 7 days; in trip add conventional treatment ） and a control group （ n = 25, phentolamine 20 mg / day, 7 days, in trip add conventional treatment ） observed the changes in each group and intergroup of cardiac function before and after treatment, and the changes and effects by classification of cardiac function, echocardiography measurements of pulmonary artery pressure. Result： The results of the two groups compared to cardiac function were improved in varying degrees after treatment , but the treatment group was pronounced more significant to the control group , At the same time, the treatment group significantly decreased pulmonary arterial pressure. Conclusion： The effects of amrinone on patients with chronic pulmonary heart disease are remarkable and safety.

关 键 词：氨力农 肺心病 肺动脉压力 心力衰竭 

分 类 号：R541.5[医药卫生—心血管疾病]